Skip to main content

Table 2 Potential predictive factors and risk of SN metastases

From: Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients

Determinants

Category

SN negative

SN positive

OR 95% CI

OR 95% CIa

Screening

No

719

343

1.00

1.00

Yes

1123

312

0.59(0.49–0.70)

0.63(0.51–0.80)

Unknown

39

16

0.86(0.48–1.57)

0.88(0.46–1.66)

Age

≤ 50

337

162

1.00

1.00

51–74

1290

412

0.67(0.53–0.82)

0.92(0.63–1.37)

≥ 75

254

97

0.80(0.59–1.08)

0.70(0.42–1.11)

Menopause Status

Pre

348

164

1.00

1.00

Post < 5 years

168

60

0.76(0.53–1.08)

0.98(0.62–1.53)

Post ≥ 5years

1299

422

0.69(0.56–0.86)

0.82(0.56–1.22)

Unknown

66

25

0.80(0.49–1.32)

0.89(0.50–1.53)

Tumor size

T1

1138

367

1.00

1.00

T2

346

213

1.91(1.56–2.34)

1.84(1.47–2.33)

T3 and T4

13

12

2.87(1.30–6.32)

2.56(1.07–6.09)

Unknown

384

79

0.63(0.49–0.83)

0.67(0.50–0.93)

Tumor type

Ductal

1325

542

1.00

1.00

D and L

35

17

1.19(0.66–2.13)

1.01 (0.54–1.90)

Lobular

217

88

1.00(0.77–1.30)

0.87(0.64–1.20)

Others

306

24

0.20(0.12–0.30)

0.29(0.18–0.46)

Histological grade

I

488

134

1.00

1.00

II

807

305

1.37(1.09–1.73)

1.02(0.80–1.31)

III

563

227

1.46(1.14–1.87)

1.10(0.82–1.50)

Unknown

23

5

0.79(0.29–2.12)

1.40(0.46–4.31)

Estrogen receptor

Positive

1538

606

1.00

1.00

Negative

218

61

0.71(0.52–0.96)

0.64(0.42–0.99)

Unknown

125

4

0.09(0.03–0.22)

0.06(0.00–0.82)

Progesterone receptor

Positive

1320

531

1.00

1.00

Negative

436

135

0.77(0.61–0.96)

0.78(0.56–1.07)

Unknown

125

5

0.10(0.04–0.24)

3.80(0.30–47.42)

Her-2 status

Negative

1041

423

1.00

1.00

Positive

174

66

0.93(0.69–1.27)

0.84(0.60–1.20)

Unknown

666

182

0.68(0.56–0.82)

0.98(0.78–1.24)

Multifocality

No

1184

386

1.00

1.00

Yes

208

144

2.12(1.67–2.70)

1.90(1.45–2.47)

Unknown

489

141

0.89(0.71–1.10)

0.86(0.67–1.09)

Vascular invasion

No

1056

268

1.00

1.00

 

Yes

87

97

4.40(3.20–6.04)

3.74(2.66–5.27)

 

Unknown

738

306

1.63(1.36–1.98)

2.10(1.68–2.62)

  1. aAdjusted including screening, age, menopause status, tumor size, tumor type, histological grade, estrogen status, progesterone status, Her-2 status, multifocality, and vascular invasion